Remisid (nimesulide) gel 1% 30 g. tube

Description

Remisid (nimesulide) gel 1% 30 g. tube

Composition

active substance: nimesulide;

1 g of gel contains nimesulide 10 mg;

auxiliary substances: dimethyl sulfoxide, propylene glycol, levomenthol, macrogol 400, carbomer 980, trometamol, purified water.

Medicinal form

Gel.

The main physical and chemical properties: gel yellow or yellow with a greenish tint, almost transparent with a weak specific smell. It should be uniform in appearance.

Pharmacotherapeutic group

Nonsteroidal anti-inflammatory drugs for local use.
ATX code M02A A26.

Pharmacological properties

Remisid is a nonsteroidal anti-inflammatory drug (NSAID), a selective inhibitor of cyclooxygenase-2. In terms of anti-inflammatory activity, nimesulide in an equimolar concentration in the initial stage of inflammation is comparable to indomethacin and piroxicam. By inhibiting the synthesis of prostaglandins in the area of ​​inflammation, nimesulide practically does not affect the synthesis of regulatory prostaglandins in the wall of the stomach and kidneys. Suppresses the activity of platelet activation factor, tumor necrosis factor α, proteinases, histamine, and the formation of free oxygen radicals. When used externally, it causes a reduction or disappearance of pain in the area of ​​application, including pain in the joints, at rest and during movement, reduces morning stiffness and swelling of the joints, helps increase the range of motion.

Indications for use

The drug Remisid is used and prescribed as a local treatment of pathologies of the musculoskeletal system, which are characterized by inflammation, pain and stiffness of movement, such as: periarthritis, osteoarthritis, post-traumatic tendonitis, muscle strain, tendosynovitis and heavy physical stress on the joints.

Contraindications

The drug Remisid is contraindicated for use in: infectious skin diseases, dermatitis, damage to the epidermis, as well as in the presence of hypersensitivity to the constituent components and in childhood. Do not use the gel in patients with allergic reactions (rhinitis, bronchospasm, urticaria) to acetylsalicylic acid or other drugs that inhibit prostaglandin synthesis.
The drug is used with extreme caution in: congestive heart failure, impaired liver and kidney function, ulcers in the acute stage, gastroduodenal bleeding or severe blood coagulation disorders and in old age.

Pregnancy and breastfeeding period

The use of the drug Remisid is contraindicated in pregnant women and nursing mothers.

Mode of application

The drug Remisid is intended for external use.
The gel is applied in a thin layer on painful areas of the body and lightly rubbed into the skin 3-4 times a day with massage movements.
The duration of therapy is determined for each patient individually, depending on the effectiveness of treatment, but not more than 1 month.
Wash and dry the skin before applying the gel.
Do not use the drug on damaged skin, on open wounds, under airtight dressings, and avoid getting the gel on the mucous membranes and eyes.

Overdose

If you use Remisid gel in doses that significantly exceed the recommended dosages or on large areas of the skin, such overdose symptoms are possible: headache, dizziness, dyspepsia and pain in the epigastric region.
If any signs of intoxication appear, symptomatic treatment should be applied, the drug should be discontinued or the dose should be reduced.

Adverse reactions

The use of Remisid gel can cause skin irritation (rash, erythema, itching, peeling, allergic reactions), and sometimes anaphylactic reactions in the form of Quincke, suffocation, vasomotor rhinitis, bronchospasm are possible.